pharma giants
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
UK's GSK to acquire U.S. drugmaker Nuvalent for $10.6 billion as pharma giants race to expand pipelines
U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its lung cancer pipeline, in what would be the British drugmaker's largest acquisition in more than a decade. The all-cash deal values Nuvalent at about $124 per share, according to a GSK filing on Tuesday, representing a 40% premium to its last closing price. The Financial Times had reported the transaction earlier on Tuesday.
US pharma giant is unhappy with Germany; CEO calls planned healthcare reform ‘terrible’
US pharmaceutical giant Eli Lilly has announced that it is halving its massive €2.3 billion ($2.67 billion) investment plan to build a high-tech manufacturing plant in Alzey, Rhineland-Palatinate in what can be seen a major blow to Germany’s industrial ambitions. The rollback targets a facility originally designed to be one of Eli Lilly’s largest and most modern factories worldwide, intended to produce its highly sought-after weight-loss and diabetes injection, Mounjaro. Eli Lilly CEO Dave...
Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology
U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Global biopharma M&A is experiencing a sharp uptick, putting the sector on track for its strongest year since the pre-pandemic peak seven years ago. Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking so far in 2026 amounted to $106 billion over 201 deals, according to PitchBook data. If the current pace of biopharma M&A holds up for the rest of the year, the industry could be on track to notch more than $250 billion in...
Race to develop Ebola vaccine as deadly strain of virus spreads
Race to develop Ebola vaccine heats up amid deadly outbreak in DRC Tue 2 Jun 2026 at 7:58am In short: Efforts have ramped up to develop a vaccine for the rare strain of Ebola amid a deadly outbreak in the Democratic Republic of Congo. More than 1,100 people are infected with the strain in the DRC and Uganda, though the true extent of the virus's spread is feared to be much wider. The WHO estimated it would take seven to nine months before the new vaccine will be ready to be tested on humans.
We're picking up more shares of an out-of-favor stock with a bright future
We are buying 50 shares of Johnson & Johnson at roughly $221.43. Following the trade, Jim Cramer's Charitable Trust will own 340 shares of JNJ, increasing its weighting to 1.9% from 1.62%. We're picking up shares of J & J here and lowering our average cost basis as healthcare and drug stocks move lower on Monday.
How Middle East conflict is rewriting your kitchen math — Explained in 10 charts
Whether you care about geopolitics or not, your monthly budget has already become an unwilling expert in it! From your morning chai to late-night dessert cravings, the Middle East crossfire is quietly sneaking into your kitchen bills, one price tag at a time. But thankfully, not everything in your grocery list is feeling the heat!